These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. 1 alpha-hydroxy vitamin D3 treatment of non-dialyzed patients with chronic renal failure. Effects on bone, mineral metabolism and kidney function. Nielsen HE; Rømer FK; Melsen F; Christensen MS; Hansen HE Clin Nephrol; 1980 Mar; 13(3):103-8. PubMed ID: 7379358 [TBL] [Abstract][Full Text] [Related]
8. Metabolic effects of 1alpha-hydroxycholecalciferol on renal osteodystrophy. Castells S; Shai F; Gauthier B; Hashemi SE; Reddy CM; De Luca HF Curr Ther Res Clin Exp; 1976 Mar; 19(3):410-9. PubMed ID: 817872 [No Abstract] [Full Text] [Related]
9. Assessment of bone mineral content in patients with chronic renal failure. Gava A; Zorzetto M; Coghetto F; Teodori T; Marazzato G Rays; 1986; 11(3):67-70. PubMed ID: 3602467 [No Abstract] [Full Text] [Related]
10. [Bone mineral content and serum 25-hydroxycholecalciferol (author's transl)]. Shiraki M; Nakao J; Yoshida A; Yamauchi H; Orimo H Nihon Ronen Igakkai Zasshi; 1979 Nov; 16(6):506-12. PubMed ID: 529540 [No Abstract] [Full Text] [Related]
11. The treatment of uraemic osteopathy. II. The effect of 5,6-trans-25-hydroxycholecalciferol in terminal renal failure. von Herrath D; Kraft D; Grigoleit H; Schaefer K Ger Med; 1973; 3(3-4):93-5. PubMed ID: 4803059 [No Abstract] [Full Text] [Related]
12. Evolution of renal osteodystrophy: correlation of bone histomorphometry and serum mineral and immunoreactive parathyroid hormone values before and after treatment with calcium carbonate or 25-hydroxycholecalciferol. Bordier PJ; Marie PJ; Arnaud CD Kidney Int Suppl; 1975 Jan; (2):102-12. PubMed ID: 1057669 [No Abstract] [Full Text] [Related]
13. [Effect of 1 alpha-hydroxycholecalciferol and of a varying phosphorus requirement on mineral metabolism in chronic renal insufficiency]. Blazheevich NV; Fernándes R; Isaeva VA; Pereverzeva OG; Alekseeva IA Vopr Med Khim; 1980; 26(1):13-23. PubMed ID: 7368619 [TBL] [Abstract][Full Text] [Related]
14. Skeletal status in patients with chronic renal disease. Christiansen C; Rodbro P; Munck O Scand J Urol Nephrol; 1976; 10(1):70-2. PubMed ID: 1273534 [TBL] [Abstract][Full Text] [Related]
15. The long-term follow-up of 195 patients with renal failure: a preliminary report. Griffiths HJ; Zimmerman RE; Lazarus M; Lowrie E; Gottlieb MN; Phillips E; Pomerantz K Radiology; 1977 Mar; 122(3):643-8. PubMed ID: 841040 [TBL] [Abstract][Full Text] [Related]
16. Influence of 1 alpha-(OH)D3 administration on bone and bone mineral metabolism in patients on chronic glucocorticoid treatment; a double blind controlled study. Braun JJ; Birkenhäger-Frenkel DH; Rietveld AH; Juttmann JR; Visser TJ; Birkenhäger JC Clin Endocrinol (Oxf); 1983 Aug; 19(2):265-73. PubMed ID: 6349865 [No Abstract] [Full Text] [Related]
17. Measurement of whole body calcium in chronic renal failure: effects of 1alpha-hydroxyvitamin D3 and parathyroidectomy. Naik RB; Dabek JT; Heynen G; James HM; Kanis JA; Robertson PW; Robinson BH; Woods CG Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():139s-145s. PubMed ID: 564247 [TBL] [Abstract][Full Text] [Related]
18. Bone mineral content in chronic renal failure and after renal transplantation. Dalén N; Alvestrand A Clin Nephrol; 1973; 1(6):338-46. PubMed ID: 4594997 [No Abstract] [Full Text] [Related]
19. Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure. Rix M; Eskildsen P; Olgaard K Nephrol Dial Transplant; 2004 Apr; 19(4):870-6. PubMed ID: 15031343 [TBL] [Abstract][Full Text] [Related]
20. Effects of 25-hydroxycholecalciferol on calcium metabolism in chronic renal failure. Letteri JM; Kleinman LM; Ellis KN; Caselnova R; Akhtar M; Cohn SH Adv Exp Med Biol; 1977; 81():591-601. PubMed ID: 899943 [No Abstract] [Full Text] [Related] [Next] [New Search]